Saturday, September 5, 2026
ExploreSearch
Via News
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document

Claude Code costs up to $200 a month. Goose does the same thing for free.

View original at venturebeat.com
VentureBeat AI - Enterprise Ai Title: Claude Code costs up to $200 a month. Goose does the same thing for free…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • When I say 'make this look modern,' Opus knows what I mean. Other models give me Bootstrap circa 2015

    80% confidence

  • It's confusing and vague. When they say '24-40 hours of Opus 4,' that doesn't really tell you anything useful about what you're actually getting

    80% confidence

  • The new rate limits affect fewer than five percent of users and target people running Claude Code continuously in the background, 24/7

    80% confidence

  • Your data stays with you, period

    80% confidence

  • I use Ollama all the time on planes — it's a lot of fun!

    80% confidence

  • You don't need to run the largest models to get excellent results

    80% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI Capital Surge Meets Investor Caution: Record Funding Rounds and Government Contracts Amid Valuation Skepticism
A single-week cluster of large AI/fintech funding rounds (Socure, Stability AI, Emerald AI, Generalist AI, Instinct, Gatik, Regent Craft) shows venture capital still pouring into AI infrastructure, identity, and autonomy plays, while Palantir's Army TITAN contract win coincided with a 6% stock drop — signaling that even flagship AI-defense revenue isn't immune to market reassessment of AI valuations. Efficiency-focused innovations like Multiverse Computing's model compression suggest the sector is also pivoting toward cost/inference economics as capital intensity draws scrutiny.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Morgan Stanley & Co. LLC
The same metric (eps) for the same entity (Morgan Stanley & Co. LLC) reported for the identical fiscal period (Q1 2026) and observation date (2026-03-31) has two conflicting values: 3.43 USD_per_share vs 3.08 USD. This is not a temporal change — both observations claim to measure the same point in time. The ~10% discrepancy (0.35 USD difference) is material for a financial metric.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,981
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,981 facts checked against source5,273 source documents archived
Query this data → isubstrate.com
Claude Code costs up to $200 a month. Goose does the same thing for free. — Source | Via News | Via News